← Back to Clinical Trials
Recruiting NCT07113288

NCT07113288 Inspire UAS High Apnea Hypopnea Index (AHI)/High Body Mass Index (BMI) Post-Approval Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07113288
Status Recruiting
Phase
Sponsor Inspire Medical Systems, Inc.
Condition Obstructive Sleep Apnea (OSA)
Study Type OBSERVATIONAL
Enrollment 70 participants
Start Date 2025-07-31
Primary Completion 2032-01-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Inspire® UAS System

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 70 participants in total. It began in 2025-07-31 with a primary completion date of 2032-01-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this observational clinical study is to provide evaluation of long-term safety and effectiveness in a newly expanded patient population including patients with a higher AHI and a higher BMI.

Eligibility Criteria

Inclusion Criteria: 1. Subject is at least 18 years of age; 2. Subject has a diagnosis of severe OSA (65 ≤ AHI ≤ 100) based on a recent sleep study (within 12 months) OR Subject has a diagnosis of moderate to severe OSA (15≤AHI≤100) AND a baseline Body Mass Index of 32\<BMI≤40 kg/m2; 3. Subject has documented failure of, or intolerance to, positive airway pressure treatments (such as CPAP or BPAP machines; NOTE: PAP failure is defined as an inability to eliminate OSA (AHI \> 15 despite PAP usage). PAP intolerance is defined as the inability to use PAP (\> 5 nights per week, 4 hours of usage per night) or unwillingness to use PAP (e.g. patient returns the PAP system after attempting to use it). 4. Subject is willing and able to have stimulation hardware permanently implanted and to use the patient remote to activate the stimulation; 5. Subject is willing and able to return for follow-up visits, undergo sleep studies (including in-lab and at-home), and complete questionnaires related to the study; 6. Subject is willing and able to provide informed consent. Exclusion Criteria: 1. Subject has a combination of central + mixed apneas \> 25% of the total apnea-hypopnea index (AHI) based on a recent sleep study (within 12 months); 2. Subject has any anatomical finding that would compromise the performance of upper airway stimulation, such as the presence of complete concentric collapse of the soft palate; 3. Subject has any condition or procedure that has compromised neurological control of the upper airway; 4. Subject is unable or does not have the necessary assistance to operate the patient remote; 5. Subject is pregnant or plans to become pregnant; 6. Subject has an implantable device that may be susceptible to unintended interaction with the Inspire System; 7. Subject has a terminal illness with life expectancy \< 12 months; 8. Any other reason the investigator deems the subject is unfit for participation in the study.

Contact & Investigator

Central Contact

Gwen Gimmestad

✉ gwengimmestad@inspiresleep.com

📞 763-392-9966

Frequently Asked Questions

Who can join the NCT07113288 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Obstructive Sleep Apnea (OSA). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07113288 currently recruiting?

Yes, NCT07113288 is actively recruiting participants. Contact the research team at gwengimmestad@inspiresleep.com for enrollment information.

Where is the NCT07113288 trial being conducted?

This trial is being conducted at Colorado Springs, United States, Bradenton, United States, Chicago, United States, Kansas City, United States and 1 additional location.

Who is sponsoring the NCT07113288 clinical trial?

NCT07113288 is sponsored by Inspire Medical Systems, Inc.. The trial plans to enroll 70 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology